Klinikum Bielefeld

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative (2021) Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article Assessment of the Severity of Atopic Dermatitis by Physicians and Patients depending on Gender: Results from the German Atopic Dermatitis Registry TREATgermany (2021) Heinrich L, Haufe E, Abraham S, Heratizadeh A, Harder , Kleinheinz A, Wollenberg A, et al. Conference contribution Fatigue and Atopic Dermatitis: Results from the German Atopic Dermatitis Registery TREATgermany (2021) Helmert C, Haufe E, Abraham S, Heratizadeh A, Harder , Kleinheinz A, Wollenberg A, et al. Conference contribution Status report on the atopic dermatitis registry TREATgermany Statusbericht zum Neurodermitisregister TREATgermany (2021) Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, Abraham S, et al. Journal article, Review article The Prevention of Positioning Injuries during Gynecologic SurgeryGuideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/077, October 2020) (2021) Fleisch MC, Bader W, Balzer K, Bennefeld L, Boeing C, Bremerich D, Gass P, et al. Journal article Dermatological Quality of Life and Neurodermatitis: Results from the German Neurodermatitis Registry TREATgermany (2021) Helmert C, Haufe E, Abraham S, Heratizadeh A, Harder I, Kleinheinz A, Wollenberg A, et al. Conference contribution THE GERMAN AD REGISTRY TREATGERMANY: RESULTS FROM AN INTERIM DATA ANALYSIS ON BASELINE CHARACTERISTICS, COMORBIDITIES AND TREATMENT HISTORY (2021) Heratizadeh A, Haufe E, Stoelzl D, Abraham S, Heinrich L, Kleinheinz A, Wollenberg A, et al. Conference contribution Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial (2021) Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, et al. Journal article Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? (2020) Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, et al. Journal article